Abstract:Background: Helicobacter pylori (H. pylori) infection is important risk factors for chronic gastritis, peptic ulcer andgastric cancer. Bismuth-containing quadruple therapy has recently been the first-line regimen recommended in manyEuropean countries but has limited efficacy in ASEAN especially Thailand. This study was aim to evaluate efficacy ofhigh dose PPI Bismuth-containing quadruple therapy with probiotics supplement for H. pylori eradication. Methods:In this double-blind randomized placebo-controlled study, H. pylori infected patients were randomized to receive 7-or14-day high dose PPI- bismuth-containing quadruple therapy with or without probiotics supplement. Probiotic was37.5 mg Lactobacillus reuteri (Biogaia®) in tablet twice daily. CYP2C19 genotyping and antibiotic susceptibility testswere also done. H. pylori eradication was defined as a negative 13C-urea breath test at least 4 weeks after treatment.Results: 100 subjects were enrolled (72 females, 28 males, mean age=54 years). Antibiotic resistance was 15.6% forclarithromycin, 34.1% for metronidazole. CYP2C19 genotyping was performed in both group and revealed 13%, 50% and37% for poor, intermediate and rapid metabolizers, respectively. Overall eradication rates of 7-day and 14-day regimenswith probiotic were 68% and 96%; P value=0.027. The eradication rate for all patients with poor and rapid metabolizerswere 100% with 14-day regimen. 14-day regimen with probiotics can provide 100% eradication with clarithromycinresistance, metronidazole resistance or dual clarithromycin and metronidazole resistance group. Furthermore, theincidence of nausea and vomiting, abdominal discomfort, and bitter taste were significantly lower in patients withprobiotics group compared with placebo (6%vs.26%, P=0.002,OR=0.126,95% CI=0.03-0.53; 4%vs.18.0%, P=0.017,OR= 0.155,95% CI=0.03-0.81 and 4%vs.26%, P= 0.001,OR= 0.08, 95%CI= 0.016-0.41, respectively). Conclusions:The 14-day high dose PPI- bismuth-containing quadruple therapy with probiotic can provide an excellent cure rate forH. pylori infection as first line treatment irrespective of CYP2C19 and antibiotic resistance pattern. Adding probioticalso significantly reduced treatment-related adverse events and improve the patients’ compliance.

A Placebo-Controlled Trial of 10-Day Bismuth-Based Quadruple Therapy to Eradicate Helicobacter Pylori Infection; a Pilot Study for the Large Linqu County Trial

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Ten-Day Bismuth-Containing Quadruple Therapy is Effective As First-Line Therapy for Helicobacter Pylori-Related Chronic Gastritis: A Prospective Randomized Study in China

Quadruple Therapy with Vonoprazan 20 Mg Daily As a First-Line Treatment for Helicobacter Pylori Infection: A Single-Center, Open-Label, Noninferiority, Randomized Controlled Trial.

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for Helicobacter pylori infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Eradication Of H Pylori Infection In A Rural Population: One-Day Quadruple Therapy Versus 7-Day Triple Therapy

Quadruple regimens using domestically manufactured drugs in gastritis and duodenal ulcer patients for Helicobacter pylori eradication:a perspective, multicenter, randomized controlled trial

Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days

Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: a randomized, multicenter clinical trial

A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication.

Non-bismuth Quadruple Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication: a Randomized Controlled Study

Comparison of high‐dose dual therapy with bismuth‐containing quadruple therapy in Helicobacter pylori‐infected treatment‐naive patients: An open‐label, multicenter, randomized controlled trial

A Multicentre Study on Eradication of Helicobacter Pylori Using Four 1-Week Triple Therapies in China.

Is Tailored Therapy Based on Antibiotic Susceptibility Effective ? a Multicenter, Open-Label, Randomized Trial

Efficacy of quadruple regimen with polaprezinc for gastric Helicobacter pylori infection eradication: protocol for a single-centre, single-blind, non-inferiority, randomised clinical trial

High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study

Efficacy of compound Lactobacillus acidophilus tablets combined with quadruple therapy for Helicobacter pylori eradication and its correlation with pH value in the stomach: a study protocol of a randomised, assessor-blinded, single-centre study

Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol

Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori

A Comparison of Doxycycline and Amoxicillin Containing Quadruple Eradication Therapy for Treating Helicobacter pylori-Infected Duodenal Ulcers: A Multicenter, Opened, Randomized Controlled Trial in China

Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial